title: Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis.
abstract: Anti-tumor necrosis factor (TNF) agents are now well regarded as highly effective treatment modalities for multiple immunologically mediated diseases, including rheumatoid arthritis, Crohn's disease and psoriasis. The mechanism of action for this particular class of medications involves the blockade of multiple intracellular signaling pathways originating from TNF-α, ultimately inducing a generalized immunosuppressed state. In fact, several cases of lymphomas have been reported in patients treated with anti-TNF-α agents, though it has been difficult to prove any degree of causality. Herein, we described a patient who developed lymphomatoid papulosis after being treated with adalimumab, whereby a clear causality could be established.
authors.affiliation: Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
authors.forename: Ji-Hye
authors.initials: JH
authors.lastname: Park
authors.forename: Jun
authors.initials: J
authors.lastname: Lee
authors.forename: Jae Hyung
authors.initials: JH
authors.lastname: Lee
authors.forename: Dong-Youn
authors.initials: DY
authors.lastname: Lee
authors.forename: Eun-Mi
authors.initials: EM
authors.lastname: Koh
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D006801:Humans; D017731:Lymphomatoid Papulosis / Q000139:chemically induced*; D008297:Male; D012878:Skin Neoplasms / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab